Vol 52, No 5 (2021)
Clinical vignette
Published online: 2021-10-28
Primary central nervous system lymphoma co-existing with ataxia–telangiectasia syndrome
1
, 1, 2, 2, 2
, 1, 2, 2, 2
Acta Haematol Pol 2021;52(5):522-524.
Abstract
Not available
Keywords: primary central nervous system lymphomaataxia-telangiectasia syndromechildren
References
- Abla O, Weitzman S, Blay JY, et al. Primary CNS lymphoma in children and adolescents: a descriptive analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG). Clin Cancer Res. 2011; 17(2): 346–352.
- Kai Y, Kuratsu J, Ushio Y. Primary malignant lymphoma of the brain in childhood. Neurol Med Chir (Tokyo). 1998; 38(4): 232–237.
- Attarbaschi A, Abla O, Ronceray L, et al. Primary central nervous system lymphoma: initial features, outcome, and late effects in 75 children and adolescents. Blood Adv. 2019; 3(24): 4291–4297.
- Küker W, Nägele T, Korfel A, et al. Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. J Neurooncol. 2005; 72(2): 169–177.
- Han CH, Bathelor TT. Diagnosis and management of primary central nervous system lymphoma. Cancer. 2017; 123(22): 4314–4324.
- Giulino-Roth L, Abla O, Batchelor TT. Management of primary central nervous system lymphoma in children. Hematology Am Soc Hematol Educ Program. 2016; 2016(1): 386–389.
- Kim SeH, Cheong JW, Park KH, et al. Comparison of ataxia-telangiectasia mutated protein expression in diffuse large B-cell lymphomas of primary central nervous system and non-central nervous system origin. Arch Pathol Lab Med. 2007; 131(3): 457–467.
- Rothblum-Oviatt C, Wright J, Lefton-Greif MA, et al. Ataxia telangiectasia: a review. Orphanet J Rare Dis. 2016; 11(1): 159.
- Attarbaschi A, Carraro E, Abla O, et al. European Intergroup for Childhood Non-Hodgkin Lymphoma (EICNHL) and the International Berlin-Frankfur t-Münster (i-BFM) Study Group. Non-Hodgkin lymphoma and pre-existing conditions: spectrum, clinical characteristics and outcome in 213 children and adolescents. Haematologica. 2016; 101(12): 1581–1591.
- Verhoeven D, Stoppelenburg AJ, Meyer-Wentrup F, et al. Increased risk of hematologic malignancies in primary immunodeficiency disorders: opportunities for immunotherapy. Clin Immunol. 2018; 190: 22–31.
